Oral and injectable semaglutide both act on the same GLP-1 receptor pathway, but injectable versions are often associated with greater average weight loss due to more consistent dosing and higher bioavailability
To learn more about youtheory and its offerings, please visit www.youtheory.com and follow along on social media @youtheory
Each pathway gives your own GLP-1 a mild boost rather than a megaphone
While more than half of employers that currently cover GLP-1s said they expected it would pay off in the long run in terms of overall health improvements, few reported seeing any evidence of that happening, contributing to long-term uncertainty
P.RamasundarahettigeC.BranchK
Yes, the SUSTAIN-6 trial showed that Ozempic significantly reduced major adverse cardiovascular events, including non-fatal heart attack and stroke, in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors